First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.

Key facts

Study ID
NCT00456261
Run by
SCRI Development Innovations, LLC
People needed
110
Starts
2007-03-01
Expected to finish
2012-09-01
Last updated by the study team
2022-05-03

Who can join

Age: 70 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.